

VINEET LABORATORIES LIMITED

CIN:L24304TG2016PLC112888

Regd Office: SY : No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.

Statement of unaudited Financial Results for the Quarter ended June 30, 2024

(All amounts are in INR Lakh)

| S No | Particulars | Quarter ended June 30, 2024 | Quarter ended March 31, 2024 | Quarter ended June 30, 2023 | Year ended 31 March 2024 |
|------|------------------------------------------------------------------------------------------------------|--------------------------------|---------------------------------|--------------------------------|-----------------------------|
| | | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| I | Income from operations | | | | |
| | a) Net Sales/income from operations | 2,386.16 | 3,704.86 | 3,752.30 | 15,059.13 |
| | Total income from operations | 2,386.16 | 3,704.86 | 3,752.30 | 15,059.13 |
| II | Other income | 37.26 | 41.07 | 2.55 | 46.32 |
| III | Total Income (I + II) | 2,423.42 | 3,745.93 | 3,754.85 | 15,105.44 |
| VI | Expenses | | | | |
| | a) Cost of materials Consumed | 1,673.87 | 3,887.09 | 3,030.31 | 13,170.41 |
| | b) Changes in inventories of finished goods, work-in progress and stock-in-trade (increase)/decrease | 222.10 | (1,347.08) | 48.23 | (1,778.50) |
| | c) Employee benefits expenses | 147.82 | 181.94 | 140.24 | 638.47 |
| | d) Finance cost | 113.85 | 172.08 | 95.88 | 478.10 |
| | e) Depreciation and amortisation expenses | 60.86 | 67.20 | 60.86 | 251.90 |
| | f) Other expenses | 421.88 | 541.36 | 507.55 | 2,308.72 |
| | Total expenses | 2,640.18 | 3,602.58 | 3,883.07 | 15,069.11 |
| V | Profit/(loss) before exceptional items and tax (III - IV) | (216.76) | 143.35 | (128.23) | 36.34 |
| VI | Exceptional items | - | - | - | - |
| VII | Profit/(loss) before Tax (V - VI) | (216.76) | 143.35 | (128.23) | 36.34 |
| VIII | Tax expense : | | | | |
| | a. Current tax (net) | - | 12.23 | - | (6.48) |
| | b. Deferred tax (net) | (3.70) | (61.26) | (3.23) | (59.89) |
| | Total tax expense | (3.70) | (49.03) | (3.23) | (66.37) |
| IX | Profit/(loss) for the period (VII-VIII) | (213.07) | 192.38 | (125.00) | 102.71 |
| X | Other comprehensive income(OCI) | | | | |
| | a) (i) Items that will not be reclassified to profit or loss | - | 1.85 | - | 1.85 |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | - | (0.47) | - | (0.47) |
| | b) (i) Items that will be reclassified to profit or loss | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - |
| | Total other comprehensive income/(loss) | - | 1.38 | - | 1.38 |
| XI | Total comprehensive income/(loss) net of tax for the Period/year (IX+X) | (213.07) | 193.76 | (125.00) | 104.09 |
| XII | Paid Up Equity Share Capital (Face Value of Rs.10/- each) | 921.90 | 921.90 | 921.90 | 921.90 |
| XIII | Other equity | | | | 2,550.53 |
| XIV | Earnings per equity share (of Rs. 10/- each) : (not annualised for the quarters) | | | | |
| | (i) Basic | (2.31) | 2.09 | (1.36) | 1.11 |
| | (ii) Diluted | (2.31) | 2.09 | (1.36) | 1.11 |

Notes

1. The above statement of unaudited financial results of M/s. Vineet Laboratories Limited ("the Company"), which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meetings held on August 13, 2024. The Statutory Auditors have carried out a limited review on the unaudited financial results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

2. No material adjustments were made in the results for the current quarter/year which pertain to earlier periods/year. Hence, the figures have not been regrouped or reclassified.

3. The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segmental reporting as per Ind AS 108 is not applicable.

4. The figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year, which were subject to limited review.

5. These Financial Results are available on the website of BSE Limited, NSE Limited and on the company's website.

For and on behalf of Board of Directors

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

Date: August 13, 2024
Place: Hyderabad



Vineet Laboratories Limited
CIN:L24304TG2016PLC112888

Regd Office: SY - No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.

Balance sheet for the Quarter ended 30 June, 2024

All amounts in Lakhs

| | Notes | As at | |
|------------------------------------------------------------------------------|-------|------------------|------------------|
| | | 30 June 2024 | 31 March 2024 |
| ASSETS | | | |
| Non-current assets | | | |
| (a) Property, plant and equipment | 3 | 2,648.35 | 2,691.53 |
| (b) Financial assets | | | |
| (i) Investments | 4 | 21.08 | 18.16 |
| (ii) Other financial assets | 5 | 141.85 | 141.95 |
| (c) Other non-current assets | 6 | 19.31 | 16.74 |
| | | 2,830.59 | 2,868.38 |
| Current assets | | | |
| (a) Inventories | 7 | 4,850.76 | 4,939.37 |
| (b) Financial assets | | | |
| (i) Trade receivables | 8 | 2,746.30 | 3,160.39 |
| (ii) Cash and cash equivalents | 9 | 124.27 | 22.78 |
| (iii) Bank balances other than (ii) above | 10 | 21.23 | 21.23 |
| (iv) Other financial assets | 5 | 2.70 | 5.86 |
| (c) Other current assets | 6 | 534.90 | 669.19 |
| | | 8,280.16 | 8,818.81 |
| | | | |
| Total assets | | 11,110.76 | 11,687.20 |
| | | | |
| EQUITY AND LIABILITIES | | | |
| Equity | | | |
| (a) Equity share capital | 11 | 921.90 | 921.90 |
| (b) Other equity | 12 | 2,337.46 | 2,550.53 |
| | | 3,259.36 | 3,472.43 |
| Liabilities | | | |
| Non-current liabilities | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 13 | 486.91 | 388.57 |
| (b) Provisions | 14 | 127.08 | 80.62 |
| (c) Deferred tax liabilities (Net) | 15 | 142.24 | 145.94 |
| | | 756.24 | 615.13 |
| | | | |
| Current liabilities | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 13 | 3,747.07 | 4,041.39 |
| (ii) Trade payables | 16 | | |
| - total outstanding dues of micro and small enterprises; | | 1,533.81 | 1,450.47 |
| - total outstanding dues of creditors other than micro and small enterprises | | 1,578.97 | 1,775.30 |
| (iii) Other financial liabilities | 17 | 26.51 | 40.81 |
| (b) Other current liabilities | 18 | 196.56 | 232.97 |
| (c) Provisions | 14 | - | 46.46 |
| (d) Current tax liabilities (net) | 19 | 12.23 | 12.23 |
| | | 7,095.15 | 7,599.63 |
| | | | |
| Total equity and liabilities | | 11,110.76 | 11,687.20 |

For and on behalf of the Board of Directors of
Vineet Laboratories Limited




G. Venkata Ramana
Managing Director
DIN: 00031873

Vineet Laboratories Limited
CIN:L24304TG2016PLC112888

Registered Office: SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India

Statement of Profit and Loss for the Quarter ended 30 June, 2024

All amounts in Lakhs

| | | For the period ended | |
|------------------------------------------------------------------------|--------------|-----------------------------|----------------------|
| | Notes | 30 June 2024 | 31 March 2024 |
| Income | | | |
| Revenue from operations | 20 | 2,386.18 | 15,059.13 |
| Other income | 21 | 37.26 | 46.32 |
| Total income | | 2,423.42 | 15,105.44 |
| Expenses | | | |
| Cost of material consumed | 22 | 1,673.87 | 13,170.41 |
| Changes in inventories of stock-in-trade | 23 | 222.10 | (1,778.50) |
| Employee benefits expense | 24 | 147.82 | 638.47 |
| Finance costs | 25 | 113.65 | 478.10 |
| Depreciation and amortisation expense | 26 | 60.86 | 251.90 |
| Other expenses | 27 | 421.88 | 2,308.72 |
| Total expenses | | 2,640.18 | 15,069.11 |
| Profit Before Tax | | (216.76) | 36.34 |
| Tax expenses | 23 | | |
| Current tax expense | | - | 12.23 |
| Deferred tax expense | | (3.70) | (59.89) |
| Taxes in respect of prior periods | | - | (18.71) |
| Total tax expenses | | (3.70) | (66.37) |
| Profit for the year | | (213.07) | 102.71 |
| Other Comprehensive Income ('OCI') | | | |
| (i) Items that will not be reclassified subsequently to profit or loss | | | |
| - Re-measurement gains/(losses) on defined benefit plans | | - | 1.85 |
| - Income tax effect on the above | | - | (0.47) |
| (ii) Items that will be reclassified subsequently to profit or loss | | - | - |
| Total other comprehensive income | | - | 1.38 |
| Total comprehensive income for the year | | (213.07) | 104.09 |
| Earnings per equity share (EPES) | | | |
| Basic and Diluted EPES (in absolute ₹ terms) | 24 | (2.31) | 1.11 |
| Nominal value per equity share (in absolute ₹ terms) | | 10.00 | 10.00 |

For and on behalf of the Board of Directors of
Vineet Laboratories Limited




G. Venkata Ramana
Managing Director
DIN: 00031873



Limited Review Report on Unaudited Financial Results of M/s Vineet Laboratories Limited

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s VINEET LABORATORIES LIMITED pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

**TO THE BOARD OF DIRECTORS OF
Vineet Laboratories Limited**

We have reviewed the accompanying unaudited financial results of **M/s Vineet Laboratories Limited**, for the quarter ended June 30, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Vineet Laboratories Limited** as at June 30, 2024.

For NSVR & Associates LLP
Chartered Accountants
FRN: 008801S/S200060

V. G. dhara N

V Gangadhara Rao N
Partner
M. No.219486
UDIN: 24219486BKFBBE7590



Place: Hyderabad
Date: 13-08-2024.